Additionally, the OS was not significantly different between both arms (HR: 0.78, 95% CI: 0.57–1.07, p = 0.12), and a significant number of secondary malignancies were observed in the HDAC group, including 2.4% of secondary leukemias and 4.3% of solid tumors [25]. Here, HDAC9 is linked to leukemia.